A Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Safety and Efficacy of Ifetroban for the Treatment of Portal Hypertension in Cirrhotic Patients
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Ifetroban (Primary) ; Ifetroban (Primary)
- Indications Liver cirrhosis; Portal hypertension
- Focus Adverse reactions
- Sponsors Cumberland Pharmaceuticals
- 14 Sep 2016 According to a Cumberland Pharmaceuticals media release, status changed from not yet recruiting to recruiting.
- 14 Sep 2016 According to a Cumberland Pharmaceuticals media release, the US FDA has cleared an IND for ifetroban facilitating initiation of this trial.
- 22 Jun 2016 New trial record